David Ambinder, MD
David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.
Articles by David Ambinder, MD
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
Enzalutamide plus leuprolide and enzalutamide monotherapy resulted in significantly MFS and a longer time to PSA progression.
The SUO meeting pays special attention to patients who responded well to NAC, the BCG shortage, trimodal therapy, and more.
Is there a better way to manage low-grade NMIBC? Adding UGN-102 to the current standard of care may be the answer.
From presentation with a testicular mass to treatment options, this provides valuable insights for community oncologists.
Drs. Bagrodia and Ambinder provide an overview of the care continuum for newly diagnosed testicular cancer patients.
Drs. Bagrodia and Ambinder walk through a community urologist's approach to a patient who presents with a testicular mass.
A recent study adds to the scant literature on preclinical bladder autotransplantation before a first-in-human trial.
Unique characteristics include higher stage at presentation and a more aggressive subsequent clinical course.
It may be time to include RPLND for patients with retroperitoneal disease following treatment for seminoma.
Dr. Surena F. Matin shared valuable insights on lymph node dissection and kidney-sparing management for UTUC.
Dr. Katie S. Murray provided insight into identifying candidates for kidney-sparing management of upper tract disease.
Does the OLYMPUS trial have practice-changing potential for patients with low-grade, low-volume UTUC?
Breaking down kidney-sparing management for UTUC, ideal patients, and SOC for endoscopic resection or ureter resection.
Data supporting lymph node dissection at time of surgery for UTUC, as well as the risk factors for individual patients.
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.